Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.25411
Abstract: Key Points Question Can casirivimab and imdevimab effectively reduce the viral load of SARS-CoV-2 with lower doses and a subcutaneous route of administration? Findings In this phase 2 randomized clinical trial of outpatients with SARS-CoV-2,… read more here.
Keywords: administration; outpatients sars; casirivimab imdevimab; imdevimab ... See more keywords